百诚医药：11月21日召开董事会会议

Group 1 - The core viewpoint of the article is that Baicheng Pharmaceutical held its fourth board meeting on November 21, 2025, to discuss the revision of the "Board Secretary Work Guidelines" [1] - For the first half of 2025, Baicheng Pharmaceutical's revenue composition was as follows: CRO business accounted for 86.22%, commercial production accounted for 10.28%, and CDMO business accounted for 3.5% [1] - As of the time of reporting, Baicheng Pharmaceutical had a market capitalization of 5.3 billion yuan [1]